AstraZeneca (LON:AZN) has been assigned a GBX 6,570 ($85.85) target price by equities research analysts at Kepler Capital Markets in a research note issued on Wednesday, Borsen Zeitung reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Kepler Capital Markets’ price objective indicates a potential upside of 7.69% from the company’s current price.
AZN has been the subject of a number of other research reports. Barclays reiterated an “overweight” rating on shares of AstraZeneca in a research note on Monday, January 21st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of AstraZeneca in a research note on Tuesday, January 22nd. Liberum Capital reiterated a “hold” rating on shares of AstraZeneca in a research note on Friday, March 29th. Goldman Sachs Group set a GBX 4,080 ($53.31) target price on shares of AstraZeneca and gave the stock a “sell” rating in a research note on Tuesday, January 1st. Finally, Societe Generale boosted their target price on shares of AstraZeneca from GBX 8,400 ($109.76) to GBX 8,500 ($111.07) and gave the stock a “buy” rating in a research note on Wednesday, January 16th. Three equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of GBX 6,307.70 ($82.42).
Shares of AZN stock opened at GBX 6,101 ($79.72) on Wednesday. The company has a debt-to-equity ratio of 136.31, a current ratio of 0.96 and a quick ratio of 0.71. The firm has a market cap of $80.25 billion and a P/E ratio of 35.89. AstraZeneca has a 12 month low of GBX 4,850 ($63.37) and a 12 month high of GBX 6,540 ($85.46).
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Featured Article: What is the yield curve?
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.